当前位置: 首页 > 期刊 > 《世界中医药》 > 201712
编号:13611495
清气化痰汤联合化疗对中晚期非小细胞肺癌痰热阻肺证患者CEA、CA125及Cyfra21—1水平的影响(4)
http://www.100md.com 2017年6月15日 《世界中医药》 201712
     [4]Xiu P,Dong XF,Li XP,et al.Clusterin:Review of research progressand looking ahead to direction in hepatocellular carcinoma[J].WorldJ Gastroenterol,2015,21(27):8262-8270.

    [5]Govindan R,Ding L,Griffith M,et al.Genomic landscape ofnon-small cell lung cancer in smokers and never-smokers[J].Cell,2012,150(6):1121-1134.

    [6]Liu MY,Li XQ,Gao TH,et al.Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients[J].J Thorac Dis,2016,8(11):3314-3322.

    [7]中华人民共和国卫生部医政司.中國常见恶性肿瘤诊治规范[M].2版.北京:北京医科大学中国协和医科大学联合出版社,1991:1-2.

    [8]王阶.中医诊疗常规[M].北京:中国医药科技出版社,2013:160-163.

    [9]陈龙邦.现代肿瘤循证诊疗手册[M].郑州:郑州大学出版社,2007:517.

    [10]Koper A,Zeef LA,Joseph L,et al.Whole Transcriptome Analysis of Pre-invasive and Invasive Early Squamous Lung Carcinoma in Archival Laser Microdissected Samples[J].Respir Res,2017,18(1):12.

    [11]Cheng Z,Shan F,Yang Y,et al.CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation:a systematic review and meta-analysis[J].BMC Med Imaging,2017,17(1):5.

    [12]郭梅,肖林,周津,等.血清CEA、NSE、CYFRA21-1联合支气管活检在周围型肺癌诊断鉴别中的应用[J].现代生物医学进展,2016,16(10):1908-1909.

    [13]Pang L,Wang J,Jiang Y,et al.Decreased levels of serum cytokeratin19 fragment CYFRA21-1 predict objrctive response to chemotherapyin patients with non-small cell lung cancer[J].Exp Ther Med,2013,6(2):355-360.

    [14]黎秀月,张军.血清CA153、CEA水平与乳腺癌骨转移的相关性研究[J].实用临床医药杂志,2012,16(11):13-16.

    [15]Lin XF,Wang XD,Sun DQ,et al.High serum CEA and CYFRA21-1levels after a two-cycle adjuvant chemotherapy for NSCLC:possiblepoor prognostic factors[J].Cancer Biol Med,2012,9(4):270-273.

    [16]马兴聪,高晓燕,闫婉君,等.黄芩素抗肿瘤机制的研究现状及最新进展[J].西部医学,2016,28(3):430.

    [17]何立丽,顾恪波.半夏提取物抗恶性肿瘤的作用机制[J].中华中医药杂志,2017,32(2):685.

    [18]常军,肖依文,吴文婷,等.苦杏仁苷抗肿瘤机理研究进展[J].药物生物技术,2014,21(6):597-599., http://www.100md.com(龚时夏 尤建良)
上一页1 2 3 4